Selected research
Industry Research
Long-acting ESAs Industry Research Report 2026
Market perspective
The global Long-acting ESAs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Long-acting ESAs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Long-acting ESAs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Long-acting ESAs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Long-acting ESAs include Amgen, Cipla, CKD Pharma, Dr. Reddy's Laboratories, Kissei Pharmaceutical, Kyowa Hakko Kirin, Sanwa Kagaku Kenkyusho, Torrent Pharmaceuticals and Hansoh Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Long-acting ESAs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Long-acting ESAs Market by Company
Amgen
Cipla
CKD Pharma
Dr. Reddy's Laboratories
Kissei Pharmaceutical
Kyowa Hakko Kirin
Sanwa Kagaku Kenkyusho
Torrent Pharmaceuticals
Hansoh Pharma
Roche
Kyowa Kirin
Long-acting ESAs Segment by Type
Pegmolesatide
Methoxy Polyethylene Glycol-Epoetin Beta
Darbepoetin Alfa
Long-acting ESAs Segment by Application
Renal Anemia
Cancer
Other
Long-acting ESAs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long-acting ESAs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Long-acting ESAs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long-acting ESAs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Long-acting ESAs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Long-acting ESAs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Long-acting ESAs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Pegmolesatide
- Methoxy Polyethylene Glycol-Epoetin Beta
- Darbepoetin Alfa
Applications
- Renal Anemia
- Cancer
- Other
Companies covered
- Amgen
- Cipla
- CKD Pharma
- Dr. Reddy's Laboratories
- Kissei Pharmaceutical
- Kyowa Hakko Kirin
- Sanwa Kagaku Kenkyusho
- Torrent Pharmaceuticals
- Hansoh Pharma
- Roche
- Kyowa Kirin
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Long-acting ESAs Market Size (2021-2032)
- 2.2.2 Global Long-acting ESAs Sales (2021-2032)
- 2.2.3 Global Long-acting ESAs Market Average Price (2021-2032)
- 2.3 Long-acting ESAs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Pegmolesatide
- 2.3.3 Methoxy Polyethylene Glycol-Epoetin Beta
- 2.3.4 Darbepoetin Alfa
- 2.4 Long-acting ESAs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Renal Anemia
- 2.4.3 Cancer
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Long-acting ESAs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Long-acting ESAs Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Long-acting ESAs Revenue of Manufacturers (2021-2026)
- 3.4 Global Long-acting ESAs Average Price by Manufacturers (2021-2026)
- 3.5 Global Long-acting ESAs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Long-acting ESAs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Long-acting ESAs, Product Type & Application
- 3.8 Global Manufacturers of Long-acting ESAs, Established Date
- 3.9 Global Long-acting ESAs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Amgen
- 4.1.1 Amgen Company Information
- 4.1.2 Amgen Business Overview
- 4.1.3 Amgen Long-acting ESAs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Amgen Long-acting ESAs Product Portfolio
- 4.1.5 Amgen Recent Developments
- 4.2 Cipla
- 4.2.1 Cipla Company Information
- 4.2.2 Cipla Business Overview
- 4.2.3 Cipla Long-acting ESAs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Cipla Long-acting ESAs Product Portfolio
- 4.2.5 Cipla Recent Developments
- 4.3 CKD Pharma
- 4.3.1 CKD Pharma Company Information
- 4.3.2 CKD Pharma Business Overview
- 4.3.3 CKD Pharma Long-acting ESAs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 CKD Pharma Long-acting ESAs Product Portfolio
- 4.3.5 CKD Pharma Recent Developments
- 4.4 Dr. Reddy's Laboratories
- 4.4.1 Dr. Reddy's Laboratories Company Information
- 4.4.2 Dr. Reddy's Laboratories Business Overview
- 4.4.3 Dr. Reddy's Laboratories Long-acting ESAs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Dr. Reddy's Laboratories Long-acting ESAs Product Portfolio
- 4.4.5 Dr. Reddy's Laboratories Recent Developments
- 4.5 Kissei Pharmaceutical
- 4.5.1 Kissei Pharmaceutical Company Information
- 4.5.2 Kissei Pharmaceutical Business Overview
- 4.5.3 Kissei Pharmaceutical Long-acting ESAs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Kissei Pharmaceutical Long-acting ESAs Product Portfolio
- 4.5.5 Kissei Pharmaceutical Recent Developments
- 4.6 Kyowa Hakko Kirin
- 4.6.1 Kyowa Hakko Kirin Company Information
- 4.6.2 Kyowa Hakko Kirin Business Overview
- 4.6.3 Kyowa Hakko Kirin Long-acting ESAs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Kyowa Hakko Kirin Long-acting ESAs Product Portfolio
- 4.6.5 Kyowa Hakko Kirin Recent Developments
- 4.7 Sanwa Kagaku Kenkyusho
- 4.7.1 Sanwa Kagaku Kenkyusho Company Information
- 4.7.2 Sanwa Kagaku Kenkyusho Business Overview
- 4.7.3 Sanwa Kagaku Kenkyusho Long-acting ESAs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Sanwa Kagaku Kenkyusho Long-acting ESAs Product Portfolio
- 4.7.5 Sanwa Kagaku Kenkyusho Recent Developments
- 4.8 Torrent Pharmaceuticals
- 4.8.1 Torrent Pharmaceuticals Company Information
- 4.8.2 Torrent Pharmaceuticals Business Overview
- 4.8.3 Torrent Pharmaceuticals Long-acting ESAs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Torrent Pharmaceuticals Long-acting ESAs Product Portfolio
- 4.8.5 Torrent Pharmaceuticals Recent Developments
- 4.9 Hansoh Pharma
- 4.9.1 Hansoh Pharma Company Information
- 4.9.2 Hansoh Pharma Business Overview
- 4.9.3 Hansoh Pharma Long-acting ESAs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Hansoh Pharma Long-acting ESAs Product Portfolio
- 4.9.5 Hansoh Pharma Recent Developments
- 4.10 Roche
- 4.10.1 Roche Company Information
- 4.10.2 Roche Business Overview
- 4.10.3 Roche Long-acting ESAs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Roche Long-acting ESAs Product Portfolio
- 4.10.5 Roche Recent Developments
- 4.11 Kyowa Kirin
- 4.11.1 Kyowa Kirin Company Information
- 4.11.2 Kyowa Kirin Business Overview
- 4.11.3 Kyowa Kirin Long-acting ESAs Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Kyowa Kirin Long-acting ESAs Product Portfolio
- 4.11.5 Kyowa Kirin Recent Developments
5 Global Long-acting ESAs Market Scenario by Region
- 5.1 Global Long-acting ESAs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Long-acting ESAs Sales by Region: 2021-2032
- 5.2.1 Global Long-acting ESAs Sales by Region: 2021-2026
- 5.2.2 Global Long-acting ESAs Sales by Region: 2027-2032
- 5.3 Global Long-acting ESAs Revenue by Region: 2021-2032
- 5.3.1 Global Long-acting ESAs Revenue by Region: 2021-2026
- 5.3.2 Global Long-acting ESAs Revenue by Region: 2027-2032
- 5.4 North America Long-acting ESAs Market Facts & Figures by Country
- 5.4.1 North America Long-acting ESAs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Long-acting ESAs Sales by Country (2021-2032)
- 5.4.3 North America Long-acting ESAs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Long-acting ESAs Market Facts & Figures by Country
- 5.5.1 Europe Long-acting ESAs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Long-acting ESAs Sales by Country (2021-2032)
- 5.5.3 Europe Long-acting ESAs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Long-acting ESAs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Long-acting ESAs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Long-acting ESAs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Long-acting ESAs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Long-acting ESAs Market Facts & Figures by Country
- 5.7.1 South America Long-acting ESAs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Long-acting ESAs Sales by Country (2021-2032)
- 5.7.3 South America Long-acting ESAs Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Long-acting ESAs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Long-acting ESAs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Long-acting ESAs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Long-acting ESAs Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Long-acting ESAs Sales by Type (2021-2032)
- 6.1.1 Global Long-acting ESAs Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Long-acting ESAs Sales Market Share by Type (2021-2032)
- 6.2 Global Long-acting ESAs Revenue by Type (2021-2032)
- 6.2.1 Global Long-acting ESAs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Long-acting ESAs Revenue Market Share by Type (2021-2032)
- 6.3 Global Long-acting ESAs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Long-acting ESAs Sales by Application (2021-2032)
- 7.1.1 Global Long-acting ESAs Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Long-acting ESAs Sales Market Share by Application (2021-2032)
- 7.2 Global Long-acting ESAs Revenue by Application (2021-2032)
- 7.2.1 Global Long-acting ESAs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Long-acting ESAs Revenue Market Share by Application (2021-2032)
- 7.3 Global Long-acting ESAs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Long-acting ESAs Value Chain Analysis
- 8.1.1 Long-acting ESAs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Long-acting ESAs Production Mode & Process
- 8.2 Long-acting ESAs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Long-acting ESAs Distributors
- 8.2.3 Long-acting ESAs Customers
9 Global Long-acting ESAs Analyzing Market Dynamics
- 9.1 Long-acting ESAs Industry Trends
- 9.2 Long-acting ESAs Industry Drivers
- 9.3 Long-acting ESAs Industry Opportunities and Challenges
- 9.4 Long-acting ESAs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst